Tularik Inc. (acquired by Amgen Inc.)

Brief Description

Tularik, Inc. engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company’s drugs include T67, T607, T131, T71, and T487. The T67 is an anti-cancer drug. The T607 would be used for treating gastric cancer and esophageal cancer. The T131 would be used for treating diabetes. The T71 would be used for treating obesity.

Tularik Inc. was acquired by Amgen Inc. for approximately $1.3 billion in 2004.

Inventor

Tech Category

  • Medical Therapeutics

Join the IPIRA Mailing List

 

 
 
 
 

 

Accessibility | Nondiscrimination | Privacy